Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
PlushCare appears to treat compounded medication as a limited fallback rather than the core program
Novartis is investing in expanding Pluvicto's label into pre-taxane prostate cancer (SPLASH trial submission pending), and developing next-generation RLT approaches targeting breast cancer and other tumour types positioning it to maintain leadership in the highest-growth oncology peptide segment
Understanding why semaglutide fails: the five core reasons Before jumping to tirzepatide as the answer, you need to understand why semaglutide did not work
As of early 2026, the orforglipron story is approaching a decisive moment
US$ 20.03
US$ 28.41
US$ 22.13
US$ 23.86
US$ 24.69
